

Case IPR2016-01096  
Patent No. 6,667,061  
Motion to Exclude Evidence  
Attorney Docket No. 9LUYE 7.1R-004

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

LUYE PHARMA GROUP LTD., LUYE PHARMA(USA) LTD., SHANDONG  
LUYE PHARMACEUTICAL CO., LTD., and NANJING LUYE  
PHARMACEUTICAL CO., LTD.,  
Petitioners,

v.

ALKERMES PHARMA IRELAND LTD and  
ALKERMES CONTROLLED THERAPEUTICS, INC.,  
Patent Owners.

Patent No. 6,667,061 to Ramstack *et al.*  
Issue Date: December 23, 2003  
Title: PREPARATION OF INJECTABLE  
SUSPENSIONS HAVING IMPROVED INJECTABILITY

---

*Inter Partes* Review No. IPR2016-01096

---

**PETITIONERS' MOTION TO EXCLUDE EVIDENCE**

**Mail Stop: Patent Board**  
Patent Trial and Appeal Board  
U.S. Patent And Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TABLE OF CONTENTS**

	<b><u>Page</u></b>
TABLE OF AUTHORITIES .....	iii
EXHIBIT LIST .....	iv
I. INTRODUCTION .....	1
II. ARGUMENT.....	2
A. Exhibits 2034, 2036, 2038-2040 And 2052 And The Declarations That Rely On Them Should Be Excluded.....	2
1. The CMC Exhibits Should Be Excluded As Impermissible Hearsay.....	4
2. The CMC Exhibits Should Be Excluded As They Lack Authentication.....	5
3. The CMC Exhibits Should Be Excluded as Irrelevant Under FRE 401/402 .....	8
4. The Gehrke Declaration And Portions Of The Berkland Declaration Should Be Excluded Under FRE 401/402 .....	10
a. Gehrke Declaration (Ex.2059).....	10
b. Berkland Declaration (Ex.2014).....	12
B. Exhibit 2049 Should Be Excluded As Hearsay Under FRE 802.....	12
C. Exhibits 2022-2030, 2035, 2037, 2042 And 2044 Should Be Excluded As Irrelevant Under FRE 401/402 .....	13
D. Exhibits 2020-2021, 2047, And 2056-2058 Are Not Cited And Should Be Excluded As Irrelevant Under FRE 401/402.....	14
III. CONCLUSION.....	15

Case IPR2016- 01096  
Motion to Exclude Evidence  
Patent No. 6,667,061  
Attorney Docket No. 9LUYE 7.1R-004

**TABLE OF AUTHORITIES**

	<b>Page(s)</b>
<b>CASES</b>	
<i>Autoquip, Inc. v. Graco Minn., Inc.</i> , IPR2013-00452, Paper 18, at 16 (P.T.A.B. Jan. 14, 2015) .....	9
<i>CNET Networks, Inc. v. Etilize, Inc.</i> , 584 F. Supp. 2d 1260 (N.D. Cal. 2008).....	9
<i>EMC Corp. v. Personalweb Techs., LLC</i> , IPR2013-00084, Paper 64, at 45-46 (P.T.A.B. May 15, 2014) .....	7
<i>Google, Inc. v. Michael Meiresonne</i> , IPR2014-01188, Paper 38, at 9-10 (P.T.A.B. Jan. 20, 2016) .....	4, 13
<i>In re Homestore.com, Inc. Sec. Litig.</i> , 347 F. Supp. 2d 769 (C.D. Cal. 2004) .....	8
<i>Shimano Inc. v. Globberide, Inc.</i> , IPR2015-00273, Paper 40, at 26-27 (P.T.A.B. June 16, 2016) .....	5
<i>SK Innovation Co. v. Celgard, LLC</i> , IPR2014-00680, Paper 57, at 27 (P.T.A.B. Sept. 25, 2015).....	14
<i>St. Luke’s Cataract &amp; Laser Inst., P.A. v. Sanderson</i> , No. 8:06-223, WL 1320242 (M.D. Fla. May 12, 2006) .....	8
<i>Standard Innovation Corp. v. Lelo, Inc.</i> , IPR2014-00148, Paper 41, at 10 (P.T.A.B Apr. 23, 2015) .....	7
<i>TRW Auto. U.S. LLC v. Magna Elecs. Inc.</i> , IPR2014-01348, Paper 25, at 5-12 (P.T.A.B. Jan. 15, 2016) .....	6
<i>Victaulic Co. v. Tieman</i> , 499 F.3d 227 (3d Cir. 2007), <i>as amended</i> (Sept. 18, 2007) .....	7, 8

Case IPR2016- 01096  
Motion to Exclude Evidence  
Patent No. 6,667,061  
Attorney Docket No. 9LUYE 7.1R-004

**STATUTES, RULES & OTHER AUTHORITIES**

37 C.F.R. § 42.62(a).....2  
37 C.F.R. § 42.64(b)(1).....2  
37 C.F.R. § 42.64(c).....1  
FRE 401 .....*passim*  
FRE 402 .....*passim*  
FRE 801 .....4, 12, 13  
FRE 802 .....*passim*  
FRE 803(6).....13  
FRE 901 .....*passim*

...

Case IPR2016- 01096  
 Motion to Exclude Evidence  
 Patent No. 6,667,061  
 Attorney Docket No. 9LUYE 7.1R-004

**EXHIBIT LIST**

<b>Exhibit #</b>	<b>Reference</b>
1001	U.S. Patent No. 6,667,061 (“the Patent”)
1002	Declaration of Dr. Patrick P. DeLuca
1003	<i>Curriculum Vitae</i> of Dr. Patrick P. DeLuca
1004	Intentionally Left Blank
1005	International Publication No. WO 95/13799 (“Ramstack”)
1006	U.S. Pharmacopeia Entry re: CMC, viscosity at 274-75, 1840 (1994)
1007	EP Pharmacopoeia Entry re: CMC, at 547-48(3d ed. 1997)
1008	Handbook of Pharmaceutical Excipients at 78-81, 135-38, 294-95, 329-330, 375-78, 420-21, 439-42, 477-80, 481-82 (2nd ed. 1994)
1009	U.S. Patent No. 5,654,010 (“Johnson”)
1010	U.S. Patent No. 5,656,299 (“Kino”)
1011	International Publication No. WO199714408 (“Gustafsson”)
1012	Intentionally Left Blank
1013	Intentionally Left Blank
1014	Herbert A. Lieberman <i>et al.</i> (eds.), <i>Pharmaceutical Dosage Forms: Disperse Systems</i> , Vol.2, at 26-35, 40, 43-46, 261, 285-318 (2nd ed. rev. expanded 1996)
1015	U.S. Patent No. 6,495,164 (“the ’164 Patent”)
1016	Serial No. 10/259,949, Office Action, Apr. 9, 2003
1017	Serial No. 10/259,949, Applicants’ Resp., May 14, 2003
1018	Serial No. 09/577,875, Declaration of Mark A. Tracy, May 17, 2002
1019	Serial No. 10/259,949, Notice of Allowability, July 24, 2003
1020	Kenneth E. Avis <i>et al.</i> (eds.), 1 (Chs.2, 4, 5) <i>Pharmaceutical Dosage Forms: Parenteral Medications</i> 17-25, 115-16, 140-43, 150-51, 173-75, 190-212 (2nd ed. rev. expanded Marcel Dekker, Inc. 1992)
1021	Leon Lachman, PhD <i>et al.</i> , <i>The Theory and Practice of Industrial Pharmacy</i> 642-44, 783-84 (Lea & Febiger 3rd ed. 1986)
1022	Herbert A. Lieberman <i>et al.</i> , <i>Pharmaceutical Dosage Forms: Disperse Systems</i> , Vol.1, at 287-313 (2nd ed. rev. expanded 1996)
1023	Orange Book entries for RISPERDAL <sup>®</sup>
1024	Supplemental Declaration of Dr. Patrick P. DeLuca, June 9, 2017
1025	Intentionally left blank

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.